Musella Foundation Awards Grant to Tocagen
to Support Clinical Study of Toca 511 & Toca FC in Brain Cancer Patients

“This grant supports an important new opportunity for patients with Grade 3 glioma,” said Al Musella, DPM, President of the Musella Foundation. “It is innovations like Toca 511 & Toca FC that we believe may make a difference in the lives of these patients.”

HEWLETT, NY, Jul. 17, 2012 /PRWeb/ — The Musella Foundation For Brain Tumor Research & Information, Inc. (Musella Foundation), a non-profit organization dedicated to improving the lives of families dealing with brain cancer, today announced that it has awarded Tocagen Inc. (http://www.tocagen.com) a grant to support the clinical investigation of Toca 511 & Toca FC in patients with recurrent Grade 3 glioma brain cancer. Tocagen is a privately held biopharmaceutical company developing novel treatments for advanced cancer, with an initial focus on brain cancer.

“This grant supports an important new opportunity for patients with Grade 3 glioma,” said Al Musella, DPM, President of the Musella Foundation. “It is innovations like Toca 511 & Toca FC that we believe may make a difference in the lives of these patients.”

Tocagen is enrolling patients across the U.S. in its investigational clinical trials of Toca 511 (vocimagene amiretrorepvec), for injection & Toca FC (flucytosine), extended-release tablets. These multicenter, open-label studies are evaluating patients with recurrent high-grade glioma, who have had prior surgery and chemoradiation. More details can be found on http://www.virtualtrials.com by searching for Tocagen under the “Find a Treatment” tab.

“Toca 511 & Toca FC has been designed to kill cancer cells from within while leaving healthy cells unharmed,” said Harry Gruber, M.D., the CEO of Tocagen. “We hope to confirm promising preclinical results for this approach in our ongoing Phase 1/2 studies in patients with Grade 3 glioma and are appreciative to the Musella Foundation for their support of this patient group in our studies.”

About the Musella Foundation

The Musella Foundation For Brain Tumor Research & Information, Inc is a 501(c)3 non- profit organization dedicated to speeding up the search for the cure of brain tumors, as well as helping families deal with the diagnosis of brain cancer, by funding innovative brain tumor research, education, advocacy and support for families that are dealing with brain tumors and organizing the brain tumor community to work together as an army to fight the disease. The Musella Foundation is responsible for maintaining the following websites:

http://www.virtualtrials.com – “Clinical Trials and Noteworthy Treatments For Brain Tumors”
http://www.braintumorcopays.org – “Brain Tumor Copayment Assistance Program”
http://www.walktoendbraintumors.org – “The National Walk To End Brain Tumors”
http://www.greyribboncrusade.org – “Grey Ribbon Crusade”

SOURCE Tocagen Inc.

RELATED LINKS
http://www.tocagen.com

Tocagen Media Contact:
Carin Canale-Theakston
carin@canalecomm.com
1-619-849-6001
www.tocagen.com

Back to Top